Orthocell

Orthocell Financial Debt Ratio

The Financial Debt Ratio of Orthocell (OCC.AX) as of Nov 4, 2026 is 2.83 %. In the previous year, Financial Debt Ratio was 1.64 % — a change of 72.76% (higher).

Financial Debt Ratio

2.83 %

YoY

72.76%

Last updated:

Financial Debt Ratio of Orthocell is 2026 2.83 % . Financial Debt Ratio of Orthocell was 2025 1.64 % . It decreases by 72.76% higher compared to the previous year.

The Orthocell Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2019
3.68 AUD
Jan 1, 2020
2.16 AUD
Jan 1, 2021
3.22 AUD
Jan 1, 2022
1.34 AUD
Jan 1, 2023
1.90 AUD
Jan 1, 2024
2.59 AUD
Jan 1, 2025
1.64 AUD
Jan 1, 2026
2.83 AUD
The Orthocell Financial Debt Ratio history
YEARFinancial Debt RatioYoY
2.83 %+72.76%
1.64 %-36.82%
2.59 %+36.43%
1.90 %+41.81%
1.34 %-58.36%
3.22 %+48.78%
2.16 %-41.31%
3.68 %+35.96%
2.71 %+36.88%
1.98 %-0.64%
1.99 %-8.11%
2.17 %+3.18%
2.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orthocell Stock analysis

What does Orthocell do? Orthocell Ltd develops and commercializes cell therapies and related technologies focused on regenerating mobility for patients with bone and soft tissue injuries. The company's products include CelGro, a collagen medical device using SMRT manufacturing for tissue reconstruction in dental and orthopedic applications, Striate+ for dental GBR, Remplir for peripheral nerve reconstruction, and SmrtGraft for tendon repair. Autologous cell therapy, particularly its tendon cell therapy in development in the United States, targets chronic tendon injuries through advanced injectable cellular therapy for cartilage and tendon regeneration. Orthocell's primary customers are healthcare providers and medical institutions requiring advanced tissue repair solutions. The company generates revenue through the sale of its medical devices and cell therapy products, with CelGro and related SMRT manufacturing processes forming a core part of its commercial portfolio. Its autologous tendon therapy development in the U.S. represents a key growth segment targeting chronic tendon injury treatments. The company's product portfolio is structured around regenerative medicine applications, with CelGro serving dental and orthopedic markets, Striate+ specifically for dental GBR, Remplir addressing nerve reconstruction needs, and SmrtGraft focused on tendon repair. Orthocell's commercial strategy emphasizes direct sales of these products to healthcare professionals and institutions seeking innovative solutions for tissue repair and regeneration. Orthocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orthocell stock

Financial Debt Ratio of Orthocell is 2.83 % in 2026.

Financial Debt Ratio of Orthocell changed from 1.64 % to 2.83 %, representing a 72.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Orthocell since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Orthocell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Orthocell

All Key Metrics — Orthocell